portugués
instituto europeu de patentes español
oficina europea de patentes catalán
oficina europea de patents 
1
In this study, we have shown that these cells bound 125I-epo specifically.
2
The researchers used three groups of mice to test the effect of epo.
3
Neither cell lines respond to epo to differentiate.
4
Anyone who follows cycling knows about epo.
5
Binding could be displaced by the presence of unlabeled epo but not by insulin or epidermal growth factor.
6
Some received no treatment, some were injected with human epo, and some were genetically modified to produce human epo in the brain.
7
It is suggested that the absence of "high" affinity receptors may account for the lack of responsiveness of these cells to epo.
8
When used in repeated small dosages as a performance-enhancing drug, kidney-derived epo stimulates the production of red blood cells, enhancing oxygen delivery and utilization.
9
Compared to the mice that received no additional epo, the doped mice showed significantly higher running performance without the damaging increase in red blood cells.
10
What's more, it did so without causing the erythropoiesis, or elevated red blood cell counts, that typically occurs when epo is used to boost performance.
11
If brain epo makes you want to do it, without actually building the blood cells, we can now look for similar things that aren't harmful.
12
The epos is the calm quiet representation of an action in progress.
13
Baseline serum EPO levels were similar for patients with and without PTE.
14
EPO use thickens the blood and increases the risk of heart attacks.
15
We hypothesized that a link between resistin and EPO responsiveness may exist.
16
Some estimate that for every EPO user discovered, 10 others get away.
